Healthy Returns: FDA chief Marty Makary on compounded GLP-1s, vaccines and China
Makary helms the FDA in the midst of a contentious stretch for the agency, defined by massive staff and budget cuts and sweeping changes to vaccine po...
Last updated: 2026-02-23 09:20:22 ET
Makary helms the FDA in the midst of a contentious stretch for the agency, defined by massive staff and budget cuts and sweeping changes to vaccine po...
The Trump administration appears to be gearing up for a substantial response to Iran, Washington state allegedly spends millions on gender surgeries f...
The Food and Drug Administration's about-face comes a little more than a week after the agency refused to consider the company's application to market...
West Virginia has become a front line
How far can Robert Kennedy junior push state policies? West Virginia will provide an answer
With the reversal from the FDA, Moderna said it is aiming to make the vaccine available for the 2026-27 flu season.
The United States Food and Drug Administration has decided to review a new vaccine for influenza, despite rejecting the application earlier this month...
Moderna Inc (NASDAQ:MRNA, XETRA:0QF) announced that the US Food and Drug Administration (FDA) will initiate review of its investigational seasonal inf...
In February 2026, Moderna reported full-year 2025 revenue of US$1.94 billion and a net loss of US$2.82 billion, while the FDA’s vaccines ...